Mark Christian's Insider Trades & SAST Disclosures
Mark Christian's most recent trade in NeuroOne Medical Technologies Corp was a trade of 1,812 Common Stock done at an average price of $1.2 . Disclosure was reported to the exchange on Feb. 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Christian.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.16 per share. | 18 Feb 2025 | 1,812 | 291,744 | - | 1.2 | 2,102 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.16 per share. | 31 Jan 2025 | 90 | 293,556 | - | 1.2 | 104 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.83 per share. | 31 Dec 2024 | 343 | 293,646 | - | 0.8 | 283 | Common Stock |
| NeuroOne Medical Technolog... | Christianson Mark | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.62 per share. | 30 Nov 2024 | 90 | 293,989 | - | 0.6 | 56 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.97 per share. | 31 Oct 2024 | 90 | 294,079 | - | 1.0 | 87 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.99 per share. | 30 Sep 2024 | 343 | 294,169 | - | 1.0 | 340 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.80 per share. | 31 Aug 2024 | 90 | 294,512 | - | 0.8 | 72 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.76 per share. | 31 Jul 2024 | 90 | 294,602 | - | 0.8 | 68 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.80 per share. | 30 Jun 2024 | 343 | 294,692 | - | 0.8 | 274 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 06 Jun 2024 | 2,189 | 295,035 | - | 0.9 | 1,918 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 05 Jun 2024 | 25,800 | 297,224 | - | 0.9 | 22,663 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.93 per share. | 31 May 2024 | 90 | 323,024 | - | 0.9 | 84 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 30 Apr 2024 | 90 | 323,114 | - | 1.1 | 102 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.15 per share. | 21 Apr 2024 | 2,030 | 323,204 | - | 1.2 | 2,335 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 31 Mar 2024 | 90 | 325,234 | - | 1.2 | 108 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.21 per share. | 29 Feb 2024 | 90 | 325,324 | - | 1.2 | 109 | Common Stock |
| NeuroOne Medical Technolog... | Christianson Mark | Business Development Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2024 | 25,000 | 325,414 | - | 0 | Common Stock | |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 31 Jan 2024 | 90 | 300,414 | - | 1.3 | 113 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.58 per share. | 31 Dec 2023 | 90 | 300,504 | - | 1.6 | 142 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Sale of securities on an exchange or to another person at price $ 1.46 per share. | 26 Dec 2023 | 31,445 | 300,594 | - | 1.5 | 45,859 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Sale of securities on an exchange or to another person at price $ 1.35 per share. | 26 Dec 2023 | 6,848 | 332,039 | - | 1.4 | 9,269 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Sale of securities on an exchange or to another person at price $ 1.40 per share. | 21 Dec 2023 | 9,907 | 340,687 | - | 1.4 | 13,870 | Common Stock |
| NeuroOne Medical Technolog... | Christianson Mark | Business Development Director | Sale of securities on an exchange or to another person at price $ 1.40 per share. | 21 Dec 2023 | 1,800 | 338,887 | - | 1.4 | 2,520 | Common Stock |
| NeuroOne Medical Technolog... | Christianson Mark | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.46 per share. | 30 Nov 2023 | 90 | 350,594 | - | 1.5 | 131 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.02 per share. | 31 Jul 2023 | 90 | 351,044 | - | 1.0 | 92 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 30 Jun 2023 | 90 | 351,134 | - | 1.2 | 108 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.21 per share. | 31 May 2023 | 90 | 351,224 | - | 1.2 | 109 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.54 per share. | 30 Apr 2023 | 90 | 351,314 | - | 1.5 | 139 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2023 | 14,000 | 351,404 | - | 0 | Common Stock | |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2023 | 14,000 | 14,000 | - | - | Option to Purchase Common Stock | |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.61 per share. | 31 Mar 2023 | 90 | 337,404 | - | 1.6 | 145 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Sale of securities on an exchange or to another person at price $ 1.50 per share. | 21 Mar 2023 | 12,711 | 337,494 | - | 1.5 | 19,092 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Sale of securities on an exchange or to another person at price $ 1.51 per share. | 21 Mar 2023 | 11,667 | 350,205 | - | 1.5 | 17,600 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Sale of securities on an exchange or to another person at price $ 1.60 per share. | 21 Mar 2023 | 2,122 | 361,872 | - | 1.6 | 3,405 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.47 per share. | 03 Feb 2023 | 2,175 | 363,994 | - | 1.5 | 3,197 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 15,000 | 366,169 | - | 0 | Common Stock | |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Sale of securities on an exchange or to another person at price $ 6.74 per share. | 23 Jun 2021 | 11,300 | 1,077,906 | - | 6.7 | 76,200 | Common Stock |
| NeuroOne Medical Technolog... | Mark Christianson | Business Development Director | Sale of securities on an exchange or to another person at price $ 6.30 per share. | 23 Jun 2021 | 600 | 1,077,306 | - | 6.3 | 3,780 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges